In contrast to the general public’s lingering unease around generative AI tools such as ChatGPT, the biopharma industry is increasingly looking to AI as its magic cure-all for drug development. The technology’s market capitalization in the space is now forecasted to rise to $11.93 billion by 2033 (compared to just $1.73 billion this year). With 2025 upon us, this investment destines AI for an even greater role in life sciences.